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The reference strain, Mycobacterium tuberculosis
H37Rv, 19 drug-sensitive and 15 drug resistant clinical
isolates of M. tuberculosis were tested for their in
vitro susceptibility to trifluoperazine (TFP), an
antipsychotic drug, by broth dilution method. The
minimal inhibitory concentration (MIC) and minimal
bactericidal concentration (MBC) of TFP against M.
tuberculosis H37Rv were 8 and 32 mg/l, respectively.
The distribution of the sensitive and resistant isolates,
with respect to the MIC of TFP, was similar. The
distribution of the sensitive and resistant isolates,
with respect to the MBC of TFP, was different and
the difference was statistically significant. The findings
suggest that TFP is more bactericidal to drug-resistant
isolates than to the sensitive isolates.
MULTIDRUG resistant tuberculosis (MDR-TB) is being
frequently reported1. Failure to cure MDR-TB with the
currently available antitubercular drugs results in the
spread of MDR-TB in the community2. So, there is an
urgent need to find out new and potent drugs to treat
such cases and thereby prevent an emerging multi-
dimensional problem. Inhibition, by drugs, of lipid syn-
thesis in mycobacteria was considered as one of the
alternative approaches to prevent the bacterial growth.
The earlier studies3-7 showed the presence of calmodulin-
like protein in mycobacteria and its regulatory effect on
lipid metabolism and growth. A calmodulin antagonist,
trifluoperazine (TFP), was shown to inhibit the growth
of Mycobacterium tuberculosis H37Rv and an isoniazid
(INH) resistant clinical isolate of M. tuberculosis at a
concentration of 5 and 8 mg/l, respectively in Youman’s
and Karlson’s medium when grown as shake cultures8.
When grown as surface cultures in the same medium,
M. tuberculosis H37Rv was inhibited by TFP at 4 mg/l,
and INH and streptomycin-resistant clinical isolates were
inhibited, respectively at 15 and 8 mg/l (ref. 9). To
continue further research with this drug as an antimy-
cobacterial agent, it is essential to determine the sus-
ceptibility pattern of clinical isolates of M. tuberculosis
to TFP. Therefore, the present study was planned to
determine the in vitro susceptibility pattern of both
drug-sensitive and drug-resistant clinical isolates of M.
tuberculosis to TFP.
A total of 19 drug-sensitive (sensitive to the four
drugs; streptomycin, isoniazid, rifampicin and ethambu-
CURRENT SCIENCE, VOL. 73, NO. 1, 10 JULY 1997
tol) and 15 drug-resistant clinical isolates (resistant to
any one or more of the four drugs mentioned earlier)
were tested. The standard laboratory reference strain,
M. tuberculosis H37Rv, was included as control. The
cultures were randomly coded and tested.
Log phase Middlebrook 7H9 (Difco, USA) culture of
M. tuberculosis H37Rv was diluted, based on bacterial
counts in a Thoma Bacteriological Counter, to contain
106 bacilli/ml in fresh 7H9 medium and distributed, in
9.9 ml quantities, to sterile bottles. TFP (Sigma, USA)
was added in 0.1 ml quantity to attain final concentrations
of 8, 16, and 32 mg/l. The control culture received
0.1 ml distilled water. The colony-forming units (cfu)
were determined, on day 0, 3, and 7 on Lowenstein
Jensen (LJ) slopes and expressed in log10 cfu/ml. Minimal
inhibitory concentration (MIC) is defined as the lowest
concentration of the drug, in mg/l, which inhibited more
than 99% of the population in the control culture on
day 7. Minimal bactericidal concentration (MBC) is
defined as the lowest concentration of the drug, in mg/l,
which killed more than 99% of the population in the
initial inoculum. The bactericidal activity (BA) is meas-
ured as the average reduction in log10 cfu/ml/day when
exposed to the respective concentration of the drug.
All the clinical isolates and the reference strain were
grown in 7H9 medium for 7 days at 37°C. The cultures
were diluted to contain 106 bacilli/ml of fresh medium
and distributed in bottles. The drug solutions were added
to attain 8, 16, 32 and 64 mg/l. The culture bottles were
incubated for 7 days at 37°C. The cfu were determined
on day 0 for the control cultures and on day 7 for all
the cultures and the MIC, MBC and BA were determined.
Table 1. Activity of TFP against M. tuberculosis H37Rv
Viable counts (log10 cfu/ml) on day
Conc. (mg/l) 0 3 7
Nil 4.60 6.16 8.39
32 4.60 3.60 (0.33)* 2.66 (0.27)
16 4.60 4.94 4.23 (0.16)
8 4.60 5.58 6.03
*Bactericidal activity is given in the parentheses.
Table 2. Distribution of MIC and MBC of TFP against clinical
isolates of M. tuberculosis
MIC (µg/ml) MBC (µg/ml)*
Strain 8 16 32 64 8 16 32 64
Clinical (sensitive) 3 12 3 1 0 2 2 14
Clinical (resistant) 5 8 2 0 1 7 5 2
Total 8 20 5 1 1 9 7 16
*For one drug-sensitive isolate the value of MBC was not available.
Sensitive: Sensitive to streptomycin, isoniazid, rifampicin, ethambutol.
Resistant: Resistant to any one or more of the above drugs.
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Table 3. Growth, in mean log10 cfu/ml (±SD), of drug-sensitive and resistant clinical isolates of M. tuberculosis in drug free and in TFP
containing cultures
Strain
Sensitive
(n = 19)
BA
Resistant
(n = 15)
BA
Growth without TFP
Day 0 Day 7
4.76 7.09
(0.59) (0.99)
4.78 6.34
(0.54) (0.81)
Growth on day 7 with TFP (mg/l)
8 16 32
6.36 4.23 3.00
(0.56) (1.08) (0.87)
– 0.05 0.19
5.22 2.95 2.11
(1.45) (1.32) (0.60)
0.26 0.38
MIC MBC MIC : MBC
16 64 1 : 4
16 32 1 : 2
BA: Bactericidal activity.
The mean MIC, MBC and BA were determined separately
for sensitive and resistant clinical isolates.
The inhibitory and bactericidal activities of TFP against
the laboratory reference strain M. tuberculosis H37Rv
are given in the Table 1. The MIC and MBC of TFP
against M. tuberculosis H37Rv were 8 and 32 mg/l,
respectively. On day 3, the BA was found to be 0.33
with 32 mg/l and on day 7, it was 0.27 and 0.16,
respectively with 32 and 16 mg/l (Table 1).
The distribution of MIC and MBC of TFP against
the clinical isolates is shown in Table 2. The MIC was
< 16 mg/l against 15 of 19 sensitive isolates and 13 of
15 resistant isolates. The distribution of sensitive and
resistant isolates, with respect to MIC of TFP, was
similar. The MBC was < 32 mg/l against 13 of 15
resistant isolates and 64 mg/l against 14 of 18 sensitive
isolates. The distribution of sensitive and resistant isolates
with respect to MBC was different and this difference
was statistically significant (p < 0.001). The MIC : MBC
ratio was 1 : 4 for 10 of 19 sensitive isolates while it
was 1 : 2 for 12 of 15 drug-resistant isolates. The mean
MIC was 16 mg/l for both the sensitive and resistant
groups (Table 3). The mean MBC was 64 and 32 mg/l,
respectively for the sensitive and resistant isolates. On
day 7, the BA against the sensitive isolates was 0.19
and 0.05, respectively with 32 and 16 mg/l, while it
was 0.38 and 0.26 for the resistant isolates (Table 3)
and the differences were statistically significant (p < 0.01
for 16 mg/l; p < 0.002 for 32 mg/l).
The MIC of TFP for a majority of the clinical isolates
was 16 mg/l. At the time when the results of this study
were available, Reddy et al. 10 reported that the MIC of
TFP ranged from 3 to 25 mg/l and 6.5 to 12.5 mg/l,
respectively, for the drug-sensitive and drug-resistant
isolates of M. tuberculosis. These observations revealed
that the MIC of TFP against M. tuberculosis is about
80 times more than that could be achieved in human
blood after the administration of the recommended dos-
age. The plasma levels of TFP in human beings range
from 80 to 200 ng/ml when the drug was administered
at the recommended dosage of 75 to 100 mg per day
in a single dose11. Because of its very low plasma
levels, the therapeutic index of TFP could be very low
and its in vivo bactericidal activity can be doubted in
human trials. But, it was interesting to note that sig-
nificantly greater proportion of drug-resistant isolates
exhibited increased susceptibility to TFP compared to
drug-sensitive isolates. This may be attributed to the
decreased growth rate of drug-resistant isolates compared
to drug-sensitive isolates (Table 3) or to the cell wall
permeability of the organism, or to the other mechanisms
operating in bacteria. Further understanding of how the
drug-resistant isolates of M. tuberculosis are more sus-
ceptible to TFP could generate more research in drug-
resistant tuberculosis.
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